ArticleEuropean journal of nuclear medicine and molecular imaging2026
Tau-PET and CSF MTBR-tau243 comparisons validate increased tau aggregation in females.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Explanatory limitations of CSF, plasma, and MRI biomarkers for inflammation and blood-brain barrier disruption in dementia.Frontiers in aging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundFemales consistently demonstrate greater tau Positron Emission Tomography (PET) tracer signal. Although interpreted as reflecting greater Alzheimer disease (AD) pathology, it's unclear whether differences arise from biological mechanisms or methodological factors. Microtubule binding region tau species containing residue 243 (MTBR-tau243) in cerebrospinal fluid (CSF) is a biomarker of aggregated tau but avoids PET limitations such as off-target binding. Comparing tau-PET and CSF MTBR-tau243, including sex interactions, can help elucidate the origin of sex differences in tau. PURPOSE: Conduct a cross-sectional analysis of CSF MTBR-tau243 and tau-PET by sex in the Swedish BioFINDER-2 (BioFINDER-2) Study and Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight-ADRC).
methodsParticipants had CSF MTBR-tau243, tau-PET, and Aβ status defined by the CSF Aβ42/40 ratio. Tau-PET was measured using [
resultsIn both cohorts, CSF MTBR-tau243 was associated with tau-PET temporal meta-ROI burden (BioFINDER-2: β = 1.1, p = < 0.0001 and Knight-ADRC: β = 0.7, p = < 0.0001), and this association did not differ by sex (BioFINDER-2 β = 0.04, p = 0.6 and Knight-ADRC: β = 0.009, p = 0.9). Among Aβ-positive subgroups, results remained consistent for the main effect (BioFINDER-2: β = 1.1, p = < 0.0001 and Knight-ADRC: β = 0.7, p = < 0.0001) and interaction (BioFINDER-2: β = 0.04, p = 0.7 and Knight-ADRC: β = 0.06, p = 0.6).
conclusionThe lack of sex moderating the association between tau-PET and CSF MTBR-tau243 indicates that higher tau-PET signal in females reflects greater susceptibility to tau pathology rather than a methodological artifact.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.